Dr. Glenn Rosen has spent the bulk of his career engaged in basic and translational research in cancer and fibrosis. From 1993-2014, Dr. Rosen held a tenured faculty position in the Division of Pulmonary and Critical Care Medicine, Department of Medicine, Stanford University. He led a basic and translational research laboratory-his research focused on the study of dysregulated signaling in fibrosis and mechanisms of apoptosis resistance in solid tumors. He also led the clinical Interstitial Lung Disease Program at Stanford. Dr. Rosen joined Bristol-Myers Squibb (BMS) in September 2014 as a Medical Director in the Early Clinical and Translational Research Group, where he led the Phase 2 program of a lysophosphatidic acid receptor antagonist for the treatment of pulmonary fibrosis. This was followed by appointment as Therapeutic Area Head of Fibrosis and Genetically Defined Diseases. In 2016 he was selected as Head, Discovery Fibrosis Biology at Bristol-Myers Squibb, where he led the early discovery and development, and translation of pre-clinical compounds, with a disease concentration in liver and lung fibrosis. Dr. Rosen joined Coherus Biosciences, Redwood City, CA, in April, 2019, where he leads the pre-clinical and translational sciences small molecule program, which is focused on development of a novel selective PPARγ modulator for the treatment of NASH.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related